Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Approach Could Allow Red Blood Cells to be Manufactured

XTALKS VITALS NEWS

Red Blood Cells

UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Share this!

March 27, 2017 | by Sarah Hand, M.Sc.

Despite the best efforts of organizations like the Red Cross to encourage adults to donate blood, shortages still occur around the world. The blood supply is often limited for individuals with rare blood types, and large-scale natural disasters can quickly deplete the supply of safe, useable blood.

Researchers have long been working on ways to generate red blood cells in vitro, however methods using stem cells have failed to generate a consistent, sustainable supply. UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

“We have demonstrated a feasible way to sustainably manufacture red cells for clinical use,” senior study author Dr. Jan Frayne, of the School of Biochemistry at the University of Bristol, told BBC News. “We've grown litres of it.”



According to the researchers, the immature red blood cells – known as reticulocytes – produced using this method show no measurable differences compared to cells cultured in the lab. The researchers published their findings in the journal, Nature Communications.

The next step for the researchers is to pair the technology with a manufacturing system capable of producing large quantities of the lab-grown red blood cells for clinical use. Since the technique is likely to be very expensive – at least at first – the blood cells generated will likely be destined for patients with very rare blood types.

“There is a bioengineering challenge,” said Professor David Anstee, of the Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant. “To produce that much at scale is quite a challenge, and really the next phase of our work is to look at methods of expanding the yield.”

The researcher have yet to transfuse the cultured red blood cells into patients, however safety studies are likely to begin before the end of the year. The researchers say that the red blood cells could have a number of other purposes, including being used to study blood diseases.

“The first therapeutic use of a cultured red cell product is likely to be for patients with rare blood groups,” said Anstee, “because suitable conventional red blood cell donations can be difficult to source.”


Keywords: Blood, Cell Culture, Clinical Supply


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News


FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News


Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Technology Solutions for Late Phase Research: Optimising Real World Data Assets


Serialization for Late Starters – With Live Industry Research Results


Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse


The New Gold Standards of IRT Delivery for Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.